Why Vaxcyte, Inc.’s (PCVX) Stock Is Up 5.32%
As of Friday, October 09, Vaxcyte, Inc.’s PCVX share price has surged by 5.32%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Jenna Brashear
Jenna Brashear
Michael Rose
Tudor Pop
| Share Statistics | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,768.2 | $203.5 | 77% |
|
| Shares Out (Mil) | 148.9 | 55.2 | 70% |
|
| Institutional Ownership | 99.4% | 93.3% | 87% |
|
| Float (Mil) | 145.9 | 40.4 | 68% |
|
| Beta | 1.29 | 1.05 | 74% |
|
| Avg Daily Volume (000s) | 1,153 | 569 | 72% |
|
| Price Change (52-week) |
13.9% | 38.8% | 67% |
|
| Growth | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (53.8%) | (10.7%) | 6% |
|
| EPS (5yr) | (13.3%) | 15.4% | 20 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.5%) | (15.7%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($1.923) | ($7.870) | ($6.873) | |
| Month Ago EPS | ($1.961) | ($8.140) | ($7.119) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($2.050) | ($8.197) | ($7.217) | |
| Year/Year Chg | (3.6%) | 39.7% | 10.6% | |
| Financials | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($1,149) | ($44) | 1% |
|
| EPS (TTM) | ($8.067) | ($1.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($962) | ($35) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($156) | $-0 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $204 | $4 | 50% |
|
| Enterprise Value (Q1) (Mil) | $9,043 | $142 | 72% |
|
| Valuation | PCVX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.32 | 1.96 | 74% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PCVX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (37.3%) | (47.0%) | 14% |
|
| ROE | (42.7%) | (51.8%) | 16% |
|
| Liabilities to Assets | 16.7% | 29.6% | 11% |
|
| F-Score | 1 | 3 | 1% |
|
Vaxcyte, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors